Please Wait
Applying Filters...
menu
    • menu
    Coral

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Ripretinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ono Pharma Seeks Ripretinib Nod for Advanced GIST in Japan
    Ono Pharma Seeks Ripretinib Nod for Advanced GIST in Japan

    26 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-26/ono-pharma-submits-an-application-for-approval-of-ripretinib-dcc-2618-in-patients-with-advanced-ga

    PHARMIWEB
    26 Mar 2026
    Share Share
    Onco360 Chosen as National Specialty Pharmacy for QinlocK
    Onco360 Chosen as National Specialty Pharmacy for QinlocK

    20 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/20/3102647/0/en/Onco360-Has-Been-Selected-as-a-National-Specialty-Pharmacy-Partner-for-QINLOCK-ripretinib.html

    GLOBENEWSWIRE
    20 Jun 2025
    Share Share
    Medison Announces Public Formulary Listing of QINLOCK in Canadian Provinces
    Medison Announces Public Formulary Listing of QINLOCK in Canadian Provinces

    29 Sep 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/medison-pharma-announces-public-formulary-listing-of-qinlock-ripretinib-in-canadian-provinces-ontario-and-quebec-for-advanced-gastrointestinal-stromal-tumor-gist-treatment-301942841.html

    PR NEWSWIRE
    29 Sep 2023
    Share Share
    Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK
    Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK

    25 May 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230525005807/en

    BUSINESSWIRE
    25 May 2023
    Share Share
    New Therapy To Treat GIST Approved For New Zealand Patients
    New Therapy To Treat GIST Approved For New Zealand Patients

    19 Jan 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/new-therapy-to-treat-rare-gastrointestinal-stromal-tumour-approved-for-new-zealand-patients-301725538.html

    PR NEWSWIRE
    19 Jan 2023
    Share Share
    Deciphera Presents Phase 1 Single Agent Dose Escalation Data for DCC-3116
    Deciphera Presents Phase 1 Single Agent Dose Escalation Data for DCC-3116

    10 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220910005012/en

    BUSINESSWIRE
    10 Sep 2022
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.